Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of asciminib in clinical practice under the managed access program

Next Previous
Trial Profile

Safety and efficacy of asciminib in clinical practice under the managed access program

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asciminib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

  • 12 Dec 2023 updated results of the ASC use within MAP in 3 clinical centers of Russia, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 15 Jun 2023 Updated results presented at the 28th Congress of the European Haematology Association.
  • 13 Dec 2022 Two Year Updated Results(n=50) of asciminib use in clinical practice in the MAP program in 3 centers of Russia presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top